Adeno-associated viruses as liver-directed gene delivery vehicles: Focus on lipoprotein metabolism

Methods in Molecular Biology

Volumn 1027, Issue , 2013, Pages 273-307

  Lagor, William R ^a,b   Johnston, Julie C ^a   Lock, Martin ^a   Vandenberghe, Luk H ^a   Rader, Daniel J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV; Adeno associated virus; Adenovirus; Atherosclerosis; Gene delivery; Lipids; Lipoproteins; Liver; Mice; Somatic overexpression

Indexed keywords

CESIUM CHLORIDE; ENDOTOXIN; VIRUS VECTOR; LIPOPROTEIN;

ADENO ASSOCIATED VIRUS; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN HEK293; CENTRIFUGATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOPROTEIN METABOLISM; LIVER; MOUSE; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; QUALITY CONTROL; TRANSGENE; TRANSIENT TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS PURIFICATION; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; MUS;

ANIMALS; DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; LIPOPROTEINS; LIVER; MICE; TRANSGENES;

EID: 84922765841     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-369-5_13     Document Type: Article

References (67)

1. Rux JJ, Burnett RM (2004) Adenovirus structure. Hum Gene Ther 15:1167-1176
2. Stratford-erricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P (1990) Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector. Hum Gene Ther 1:241-256
3. Herz J, Gerard RD (1993) Adenovirusmediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 90:2812-2816
4. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883-893
5. Kop fl er WP, Willard M, Betz T, Willard JE, Gerard RD, Meidell RS (1994) Adenovirusmediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 90:1319-1327
6. Hughes SD, Rouy D, Navaratnam N, Scott J, Rubin EM (1996) Gene transfer of cytidine deaminase apoBEC-1 lowers lipoprotein(a) in transgenic mice and induces apolipoprotein B editing in rabbits. Hum Gene Ther 7:39-49
7. Stevenson SC, Marshall-Neff J, Teng B, Lee CB, Roy S, McClelland A (1995) Phenotypic correction of hypercholesterolemia in apoEdeficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb Vasc Biol 15:479-484
8. Spady DK, Cuthbert JA, Willard MN, Meidell RS (1995) Adenovirus-mediated transfer of a gene encoding cholesterol 7 alpha-hydroxylase into hamsters increases hepatic enzyme activity and reduces plasma total and low density lipoprotein cholesterol. J Clin Invest 96:700-709
9. Seguret-Mace S, Latta-Mahieu M, Castro G, Luc G, Fruchart JC, Rubin E, Dene fl e P, Duverger N (1996) Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 94:2177-2184
10. Applebaum-Bowden D, Kobayashi J, Kashyap VS, Brown DR, Berard A, Meyn S, Parrott C, Maeda N, Shamburek R, Brewer HB Jr, Santamarina-Fojo S (1996) Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest 97:799-805
11. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 3:137-144
12. Jooss K, Ertl HC, Wilson JM (1998) Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 72:2945-2954
13. Kass-Eisler A, Falck-edersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA (1994) The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1:395-402
14. Kozarsky KF, Donahee MH, Glick JM, Krieger M, Rader DJ (2000) Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 20:721-727
15. Tsukamoto K, Tangirala RK, Chun S, Usher D, Pure E, Rader DJ (2000) Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol Ther 1:189-194
16. Quarck R, De Geest B, Stengel D, Mertens A, Lox M, Theilmeier G, Michiels C, Raes M, Bult H, Collen D, Van Veldhoven P, Ninio E, Holvoet P (2001) Adenovirus-mediated gene transfer of human platelet-activating factoracetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103:2495-2500
17. Juan SH, Lee TS, Tseng KW, Liou JY, Shyue SK, Wu KK, Chau LY (2001) Adenovirusmediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation 104:1519-1525
18. Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, Beaudet A, Chan L (2003) Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 107:2726-2732
19. Dong J, Liu J, Lou B, Li Z, Ye X, Wu M, Jiang XC (2006) Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J Lipid Res 47:1307-1314
20. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2007) Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27:1368-1374
21. Hu Q, Zhang XJ, Zhang C, Zhao YX, He H, Liu CX, Feng JB, Jiang H, Yang FL, Zhang CX, Zhang Y (2008) Peroxisome proliferatoractivated receptor-gamma1 gene therapy attenuates atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Hum Gene Ther 19:287-299
22. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ (1999) Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100:1816-1822
23. Tsukamoto K, Tangirala R, Chun SH, Pure E, Rader DJ (1999) Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:2162-2170
24. Harris JD, Graham IR, Schepelmann S, Stannard AK, Roberts ML, Hodges BL, Hill V, Amal fi tano A, Hassall DG, Owen JS, Dickson G (2002) Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(), E3(-), polymerase(-)] adenovirus vector expressing human apoE. Hum Mol Genet 11:43-58
25. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA (2002) Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76:4580-4590
26. Goncalves MA (2005) Adeno-associated virus: From defective virus to effective vector. Virol J 2:43
27. Koeberl DD, Alexander IE, Halbert CL, Russell DW, Miller AD (1997) Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 94:1426-1431
28. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94:5804-5809
29. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK, Thompson AR, Kay MA (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16:270-276
30. Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, Yang EY, Tai SJ, Iwaki Y, Kurtzman GJ, Fisher KJ, Colosi P, Couto LB, High KA (1998) Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91:4600-4607
31. Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM (1999) Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96:3906-3910
32. Yang XP, Yan D, Qiao C, Liu RJ, Chen JG, Li J, Schneider M, Lagrost L, Xiao X, Jiang XC (2003) Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601-1607
33. Lebherz C, Gao G, Louboutin JP, Millar J, Rader D, Wilson JM (2004) Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 6:663-672
34. Kitajima K, Marchadier DH, Miller GC, Gao GP, Wilson JM, Rader DJ (2006) Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 26:1852-1857
35. Kitajima K, Marchadier DH, Burstein H, Rader DJ (2006) Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis 186:65-73
36. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ (2007) Gene transfer of wild-type apoA-I and apoA-I milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol 6:15
37. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ (2007) Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation 116:1267-1273
38. Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective virus particles. Science 149:754-756
39. Dai J, Rabie AB (2007) The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod Craniofac Res 10:1-14
40. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ, Calcedo R, Sanmiguel J, Abbas Z, Wilson JM (2003) Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci USA 100:6081-6086
41. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI (1990) Sitespeci ficintegration by adeno-associated virus. Proc Natl Acad Sci USA 87:2211-2215
42. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR (2005) Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 79:14793-14803
43. Kotin RM (1994) Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther 5:793-801
44. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF (2001) Rate limiting steps of AAV transduction and implications for human gene therapy. Curr Gene Ther 1:137-147
45. Chirmule N, Truneh A, Haecker SE, Tazelaar J, Gao G, Raper SE, Hughes JV, Wilson JM (1999) Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol 163:448-455
46. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) Crosspackaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad speci fi city. J Virol 76:791-801
47. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33-40
48. Gao G, Vandenberghe LH, Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5:285-297
49. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13:77-87
50. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16:1073-1080
51. Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA, Nakai H (2006) Robust systemic transduction with AAV9 vectors in mice: Ef fi cient global cardiac gene transfer superior to that of AAV8. Mol Ther 14:45-53
52. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolotukhin I, Tarantal AF, Byrne BJ (2006) Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99:e3-e9
53. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM (2002) Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99:11854-11859
54. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N, Wilson JM (2001) Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 75:6199-6203
55. Hayashi Y, Mori Y, Janssen OE, Sunthornthepvarakul T, Weiss RE, Takeda K, Weinberg M, Seo H, Bell GI, Refetoff S (1993) Human thyroxine-binding globulin gene: Complete sequence and transcriptional regulation. Mol Endocrinol 7:1049-1060
56. Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224-2232
57. Wright JF (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15:840-848
58. Cecchini S, Negrete A, Kotin RM (2008) Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene Ther 15:823-830
59. Van Vliet KM, Blouin V, Brument N, Agbandje-McKenna M, Snyder RO (2008) The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol 437:51-91
60. Grieger JC, Choi VW, Samulski RJ (2006) Production and characterization of adenoassociated viral vectors. Nat Protoc 1:1412-1428
61. Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, Zhou J, Hauck B, Luna J, Sommer JM, Smith P, Zhou S, Colosi P, High KA, Pierce GF, Wright JF (2007) Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 140:183-192
62. Grieger JC, Samulski RJ (2005) Adenoassociated virus as a gene therapy vector: Vector development, production and clinical applications. Adv Biochem Eng Biotechnol 99:119-145
63. Nakai H, Thomas CE, Storm TA, Fuess S, Powell S, Wright JF, Kay MA (2002) A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 76:11343-11349
64. Dodge JC, Clarke J, Passini MA, Song A, O'Riordan CR, Cheng SH, Stewart GR (2005) 497. Sex and estrous cycle stage in fl uence the ef fi ciency of AAV-mediated gene transfer in the rodent brain. Mol Ther 11:S192-S193
65. Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC (2003) Sex signi fi cantly in fl uences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102:480-488
66. Berraondo P, Crettaz J, Ochoa L, Paneda A, Prieto J, Troconiz IF, Gonzalez-Aseguinolaza G (2006) Intrahepatic injection of recombinant adeno-associated virus serotype 2 overcomes gender-related differences in liver transduction. Hum Gene Ther 17:601-610
67. Voutetakis A, Zheng C, Wang J, Goldsmith CM, A fi one S, Chiorini JA, Wenk ML, Vallant M, Irwin RD, Baum BJ (2007) Gender differences in serotype 2 adeno-associated virus biodistribution after administration to rodent salivary glands. Hum Gene Ther 18:1109-1118